Novartis (NOVN) PT Set at CHF 90 by Sanford C. Bernstein
Novartis (VTX:NOVN) has been given a CHF 90 target price by equities researchers at Sanford C. Bernstein in a research note issued on Thursday. The brokerage currently has a “buy” rating on the stock. Sanford C. Bernstein’s target price suggests a potential upside of 14.83% from the stock’s current price.
Several other research firms have also recently issued reports on NOVN. Morgan Stanley set a CHF 92 price target on shares of Novartis and gave the stock a “buy” rating in a research note on Thursday, January 25th. JPMorgan Chase set a CHF 84 price target on shares of Novartis and gave the stock a “neutral” rating in a research note on Wednesday, January 10th. Societe Generale set a CHF 95 price target on shares of Novartis and gave the stock a “buy” rating in a research note on Wednesday, March 14th. S&P Global set a CHF 91 target price on shares of Novartis and gave the stock a “neutral” rating in a research report on Thursday, January 25th. Finally, Berenberg Bank set a CHF 91 target price on shares of Novartis and gave the stock a “neutral” rating in a research report on Friday, January 26th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of CHF 88.25.
Novartis stock opened at CHF 78.38 on Thursday. Novartis has a 12-month low of CHF 72.45 and a 12-month high of CHF 88.30.
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.